Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alnylam PharmaceuticalsLTS:0HD2 -29.08%63 Graham Number is $32.23 as of Mar. 2026, which is 78% above its 10-year median of 18.09. GuruFocus rates LTS:0HD2 with a GF Score™ of 63/100 and a GF Value™ of $520.80 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 251 Biotechnology companies, Alnylam Pharmaceuticals ranks worse than 88.05% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
The historical rank and industry rank for Alnylam Pharmaceuticals's Graham Number or its related term are showing as below:
LTS:0HD2'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 5.02 Med: 18.09 Max: 49.4
Current: 5.02
During the past 13 years, the highest Price to Graham Number ratio of Alnylam Pharmaceuticals was 49.40. The lowest was 5.02. And the median was 18.09.
LTS:0HD2's Price-to-Graham-Number is ranked worse than 88.05% of 251
companies
in the Biotechnology industry
Industry Median: 1.73
vs LTS:0HD2: 5.02
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Alnylam Pharmaceuticals (LTS:0HD2) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Alnylam Pharmaceuticals's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2026 )
=
202.18
/
36.51
=
5.54
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Alnylam Pharmaceuticals Graham Number Related Terms
Alnylam Pharmaceuticals Graham Number Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HD2 vs ONC, RVMD, RPRX: Graham Number Comparison
For the Biotechnology subindustry, Alnylam Pharmaceuticals's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals Price-to-Graham-Number vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals (LTS:0HD2) has a Graham Number of $32.23 as of Mar. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on Alnylam Pharmaceuticals and its competitors. This is 78% above median its historical median of 18.09. Over the past decade, Alnylam Pharmaceuticals' Graham Number has ranged from 5.02 to 49.40. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #221 out of 251 companies in the Biotechnology industry, placing it in the top 88%.
Is Alnylam Pharmaceuticals' Graham Number too high?
Alnylam Pharmaceuticals' current Graham Number of $32.23 is 78% above median its 10-year median of 18.09. Over the past 10 years, this metric has ranged from a low of 5.02 to a high of 49.40. The Biotechnology industry median Graham Number is 1.73. Alnylam Pharmaceuticals' value of $32.23 is 1763% above this industry median. Based on the distribution chart, Alnylam Pharmaceuticals ranks #221 out of 251 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alnylam Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Graham Number compare to ONC and RVMD?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #221 out of 251 companies for Graham Number. This places Alnylam Pharmaceuticals in the lower half of its industry. The industry median Graham Number is 1.73. Alnylam Pharmaceuticals' value of $32.23 is 1763% above this benchmark. Historically, Alnylam Pharmaceuticals' own Graham Number has ranged from 5.02 to 49.40 over the past decade. While the company's 10-year median is 18.09 vs. the industry median of 1.73, Alnylam Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Biotechnology company?
The median Graham Number among Biotechnology companies is 1.73, based on 251 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alnylam Pharmaceuticals's current Graham Number of $32.23 is 1763% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Alnylam Pharmaceuticals and its competitors. For the Biotechnology industry, the median Graham Number is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alnylam Pharmaceuticals's current Graham Number is $32.23, which is 78% above median its own 10-year median of 18.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $520.80, compared to a current price of $202.18 — trading 61.2% below its estimated fair value. The current Graham Number is $32.23, which is 78% above median its 10-year median of 18.09 and 1763% above the Biotechnology industry median of 1.73. Alnylam Pharmaceuticals' overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Graham Number is $32.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $202.18 is trading 61.2% below its estimated GF Value™ of $520.80.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
Graham Number: $32.23 (78% above median its 10-year median of 18.09)
GF Value™: $520.80 vs. price of $202.18 (61.2% below fair value)
Industry Position: 1763% above the Biotechnology median (#221 of 251)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
63GF Score
Get the complete analysis for LTS:0HD2
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
